Current Opinion in Endocrinology and Diabetes was launched in 1994, with Obesity added to the title in 2007. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The fields of endocrinology and diabetes are divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce one of the Journal's Section Editor for this issue.
Peter A. Gottlieb
Dr Peter A. Gottlieb was born in Havana, Cuba, but at age 2 moved to New Jersey, USA, where he grew up. After receiving his undergraduate degree from the University of Pennsylvania, USA, he attended UMDNJ-Robert Wood Johnson Medical School, USA from which he graduated in 1984. Dr Gottlieb completed his internship and residency in internal medicine at the University of Massachusetts Medical School, USA and then continued his fellowship training in endocrinology and metabolism there as well. In 1990, after completing his fellowship, he moved to the Weizmann Institute in Israel to do post-doctoral training in T cell immunology.
After surviving Gulf War I, he returned to UMass, USA and joined the staff as Clinical Director of Diabetes. He subsequently joined the Barbara Davis Center for Childhood Diabetes in 1995, USA where he is a Professor of Pediatrics and Medicine and the Director of the Translational Research Unit at the Barbara Davis Center.
He has authored, co-authored and collaborated on more than 155 publications in peer-reviewed journals, as well as several book chapters and served as section editor for several journal editions. His research areas of interest include the immunology of type 1 diabetes, intervention trials to prevent or reverse type 1 diabetes, islet transplantation and the genetics of autoimmune disease. He had led several multi-center trials in new onset type 1 diabetes and is an active member of the Steering Committee for Type 1 Diabetes TrialNet. Most recently, he has co-founded a biotech company to develop a small molecule therapy for Type 1 diabetes.